

### Exhibit 13

### Staggering Cumulative Financial Harm: 2006-2017

### Direct "Service Fee" and US Sales Fraud

(\$ million)

	Direct "Service Fee" <u>Fraud (\$mil)<sup>1</sup></u>	US Sales <u>Fraud (\$mil)</u>	Estimated Part D Market <u>Share (%)</u>
Avonex (Biogen)	\$839	\$12,487	30%
Copaxone (Teva)	1,348	19,866	30%
Rebif (PFE/Serono)	553	8,356	30%
Betaseron (Bayer)	305	4,552	30%
Tecfidera (Biogen)	\$581	\$8,613	30%
Gilenya (Novartis)	381	5,607	30%
<b>Total</b>	<b>\$4,006</b>	<b>\$59,480</b>	<b>30%</b>
<b>Part D</b>	<b>\$1,202</b>	<b>\$17,844</b>	

<sup>1</sup> Using the PhRMA 8% average contract rate for "specialty" drugs.

Source: Corporate reports, PhRMA, PCMA, Redbook, our estimates.

**From the Second Amended District of Rhode Island (D-RI) Whistleblower Complaint; filed August 17, 2018**